Chemical inhibitors of PD-2 target various signaling pathways to impede its activity. Palbociclib, as a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6, hampers the progression of the cell cycle, which is essential for PD-2 function. The disruption of the normal progression of the cell cycle by Palbociclib consequently leads to an indirect inhibition of PD-2, as PD-2 requires specific cell-cycle stages for its activity. Similarly, Rapamycin, by inhibiting mTOR, suppresses downstream signaling that contributes to PD-2 activity. The mTOR pathway is fundamental for various cellular processes, including those that regulate PD-2 function, and Rapamycin's interference with this pathway demonstrates an indirect method of inhibiting PD-2.
Moreover, LY294002 and Triciribine target the PI3K/Akt signaling pathway, with LY294002 directly inhibiting PI3K and Triciribine targeting Akt, thereby disrupting a critical upstream regulator of PD-2. The resultant decrease in PI3K/Akt signaling can lead to a reduction in PD-2 activity. U0126 and Selumetinib, both MEK inhibitors, and PD98059, which also targets MEK, suppress the MAPK/ERK pathway, another regulator of PD-2. With reduced activity of this pathway, PD-2 activity is diminished. SB203580 and SP600125 inhibit the p38 MAPK and JNK pathways, respectively, both of which are implicated in the regulation of PD-2. Inhibition of these kinase pathways prevents the phosphorylation events that are necessary for full PD-2 activity. Additionally, PP2 and Dasatinib, by inhibiting Src family kinases, and Sunitinib, by inhibiting receptor tyrosine kinases, block signaling routes that are requisite for PD-2's functional state. The inhibition of these kinases by PP2, Dasatinib, and Sunitinib leads to a reduction in PD-2 signaling, thereby providing further methods to functionally inhibit PD-2. Each chemical, through its respective target, orchestrates a decrease in PD-2 activity by inhibiting the specific signaling pathways or kinases that are critical for PD-2's function in the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. PD-2 activity is dependent on the cell cycle, and by inhibiting CDK4/6, Palbociclib indirectly inhibits PD-2 by preventing its required cell-cycle progression. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. PD-2 function is associated with mTOR signaling, and inhibition of mTOR can suppress the downstream effects that contribute to the activation and function of PD-2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 inhibits PI3K, which is upstream of the Akt signaling pathway. Because PD-2 activity is regulated by the PI3K/Akt pathway, LY294002 can indirectly inhibit PD-2 by blocking this pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an Akt inhibitor. PD-2 is downstream of Akt, and its activity is influenced by Akt signaling. Inhibiting Akt with Triciribine can reduce the functional activity of PD-2. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor. MEK is part of the MAPK/ERK pathway which regulates PD-2 activity. Inhibiting MEK with U0126 can lead to decreased PD-2 activity by suppressing ERK signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. PD-2 is known to be regulated by the p38 MAPK pathway, and by inhibiting this pathway, SB203580 can indirectly inhibit PD-2 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, and JNK is involved in stress-activated protein kinase signaling that can regulate PD-2. By inhibiting JNK, SP600125 can decrease PD-2 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which is involved in the MAPK/ERK pathway that regulates PD-2. Inhibition of MEK by PD98059 can lead to reduced PD-2 activity. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family tyrosine kinase inhibitor. Src kinases can influence PD-2 activity, and by inhibiting these kinases, PP2 can indirectly inhibit PD-2. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor. By inhibiting MEK, Selumetinib can suppress the MAPK/ERK pathway which is necessary for PD-2 activity, leading to an indirect inhibition of PD-2. | ||||||